title: Promiscuous mutations activate the noncanonical NF-kappaB pathway in multiple myeloma.
abstract: Activation of NF-kappaB has been noted in many tumor types, however only rarely has this been linked to an underlying genetic mutation. An integrated analysis of high-density oligonucleotide array CGH and gene expression profiling data from 155 multiple myeloma samples identified a promiscuous array of abnormalities contributing to the dysregulation of NF-kappaB in approximately 20% of patients. We report mutations in ten genes causing the inactivation of TRAF2, TRAF3, CYLD, cIAP1/cIAP2 and activation of NFKB1, NFKB2, CD40, LTBR, TACI, and NIK that result primarily in constitutive activation of the noncanonical NF-kappaB pathway, with the single most common abnormality being inactivation of TRAF3. These results highlight the critical importance of the NF-kappaB pathway in the pathogenesis of multiple myeloma.
authors: Comprehensive Cancer Center, Mayo Clinic Arizona, Scottsdale, AZ 85259, USA.
authors: Jonathan J
authors: JJ
authors: Keats
authors: Rafael
authors: R
authors: Fonseca
authors: Marta
authors: M
authors: Chesi
authors: Roelandt
authors: R
authors: Schop
authors: Angela
authors: A
authors: Baker
authors: Wee-Joo
authors: WJ
authors: Chng
authors: Scott
authors: S
authors: Van Wier
authors: Rodger
authors: R
authors: Tiedemann
authors: Chang-Xin
authors: CX
authors: Shi
authors: Michael
authors: M
authors: Sebag
authors: Esteban
authors: E
authors: Braggio
authors: Travis
authors: T
authors: Henry
authors: Yuan-Xiao
authors: YX
authors: Zhu
authors: Homer
authors: H
authors: Fogle
authors: Tammy
authors: T
authors: Price-Troska
authors: Gregory
authors: G
authors: Ahmann
authors: Catherine
authors: C
authors: Mancini
authors: Leslie A
authors: LA
authors: Brents
authors: Shaji
authors: S
authors: Kumar
authors: Philip
authors: P
authors: Greipp
authors: Angela
authors: A
authors: Dispenzieri
authors: Barb
authors: B
authors: Bryant
authors: George
authors: G
authors: Mulligan
authors: Laurakay
authors: L
authors: Bruhn
authors: Michael
authors: M
authors: Barrett
authors: Riccardo
authors: R
authors: Valdez
authors: Jeff
authors: J
authors: Trent
authors: A Keith
authors: AK
authors: Stewart
authors: John
authors: J
authors: Carpten
authors: P Leif
authors: PL
authors: Bergsagel
mesh_terms: D000256:Adenoviridae; D000075747:Baculoviral IAP Repeat-Containing 3 Protein; D019013:CD40 Antigens / Q000235:genetics / Q000378:metabolism; D002478:Cells, Cultured; D000074749:Deubiquitinating Enzyme CYLD; D004789:Enzyme Activation; D005455:Fluorescent Antibody Technique; D017353:Gene Deletion; D020869:Gene Expression Profiling; D015972:Gene Expression Regulation, Neoplastic; D006801:Humans; D015151:Immunoblotting; D007124:Immunoenzyme Techniques; D017404:In Situ Hybridization, Fluorescence; D051034:Inhibitor of Apoptosis Proteins / Q000235:genetics / Q000378:metabolism; D053259:Lymphotoxin beta Receptor / Q000235:genetics / Q000378:metabolism; D009101:Multiple Myeloma / Q000235:genetics* / Q000378:metabolism / Q000473:pathology; D009154:Mutation / Q000235:genetics*; D016328:NF-kappa B / Q000235:genetics* / Q000378:metabolism; D052002:NF-kappa B p50 Subunit / Q000235:genetics / Q000378:metabolism; D052003:NF-kappa B p52 Subunit / Q000235:genetics / Q000378:metabolism; D009363:Neoplasm Proteins / Q000235:genetics / Q000378:metabolism*; D009693:Nucleic Acid Hybridization; D010957:Plasmids; D016133:Polymerase Chain Reaction; D017346:Protein Serine-Threonine Kinases / Q000235:genetics / Q000378:metabolism; D015398:Signal Transduction; D047992:TNF Receptor-Associated Factor 2 / Q000235:genetics / Q000378:metabolism; D048008:TNF Receptor-Associated Factor 3 / Q000235:genetics / Q000378:metabolism; D014162:Transfection; D053303:Transmembrane Activator and CAML Interactor Protein / Q000235:genetics / Q000378:metabolism; D025521:Tumor Suppressor Proteins / Q000235:genetics / Q000378:metabolism; D044767:Ubiquitin-Protein Ligases; D000097782:NF-kappaB-Inducing Kinase
chemical_list: D000075747:Baculoviral IAP Repeat-Containing 3 Protein; D019013:CD40 Antigens; D000074749:Deubiquitinating Enzyme CYLD; D051034:Inhibitor of Apoptosis Proteins; D053259:Lymphotoxin beta Receptor; D016328:NF-kappa B; D052002:NF-kappa B p50 Subunit; D052003:NF-kappa B p52 Subunit; D009363:Neoplasm Proteins; D017346:Protein Serine-Threonine Kinases; D047992:TNF Receptor-Associated Factor 2; D048008:TNF Receptor-Associated Factor 3; D053303:Transmembrane Activator and CAML Interactor Protein; D025521:Tumor Suppressor Proteins; D044767:Ubiquitin-Protein Ligases; D000097782:NF-kappaB-Inducing Kinase; C505697:LTBR protein, human; C489548:NFKB1 protein, human; C498206:NFKB2 protein, human; C108467:TNFRSF13B protein, human; C090656:TRAF3 protein, human; C494832:BIRC3 protein, human; C409984:CYLD protein, human
references: J Biol Chem. 2004 Jan 2;279(1):677-85
references: 14557256
references: Blood. 2003 Oct 1;102(7):2562-7
references: 12805059
references: Exp Cell Res. 2004 Aug 15;298(2):535-48
references: 15265700
references: Biostatistics. 2004 Oct;5(4):557-72
references: 15475419
references: Cell. 1991 Dec 20;67(6):1075-87
references: 1760839
references: Oncogene. 1993 Oct;8(10):2839-45
references: 8378093
references: Proc Natl Acad Sci U S A. 1996 Nov 26;93(24):13565-70
references: 8942974
references: Proc Natl Acad Sci U S A. 1996 Nov 26;93(24):13931-6
references: 8943038
references: Oncogene. 1997 Apr 17;14(15):1805-10
references: 9150386
references: J Exp Med. 1997 Oct 6;186(7):999-1014
references: 9314550
references: J Exp Med. 1998 Jan 19;187(2):147-59
references: 9432973
references: J Exp Med. 1998 Jan 19;187(2):185-96
references: 9432976
references: Nat Genet. 1999 May;22(1):74-7
references: 10319865
references: Immunity. 2004 Nov;21(5):629-42
references: 15539150
references: Proc Natl Acad Sci U S A. 2004 Dec 21;101(51):17765-70
references: 15591353
references: J Clin Oncol. 2005 Jan 20;23(3):630-9
references: 15659509
references: Blood. 2005 Jul 1;106(1):296-303
references: 15755896
references: J Biol Chem. 2005 Dec 9;280(49):40578-82
references: 16223731
references: J Gene Med. 2006 Apr;8(4):442-51
references: 16389604
references: Cancer Cell. 2006 Apr;9(4):313-25
references: 16616336
references: Immunol Rev. 2006 Apr;210:171-86
references: 16623771
references: Nature. 2006 May 25;441(7092):431-6
references: 16724054
references: Cell. 2006 Jun 30;125(7):1253-67
references: 16814713
references: Biochem Pharmacol. 2006 Oct 30;72(9):1161-79
references: 16970925
references: Oncogene. 2006 Oct 30;25(51):6831-43
references: 17072331
references: J Exp Med. 2006 Oct 30;203(11):2413-8
references: 17015635
references: Nature. 2006 Nov 23;444(7118):444-54
references: 17122850
references: Nat Genet. 2006 Dec;38(12):1413-8
references: 17115057
references: Immunity. 2006 Dec;25(6):871-83
references: 17174931
references: J Biol Chem. 2007 Feb 9;282(6):3688-94
references: 17158868
references: Blood. 2007 Apr 15;109(8):3177-88
references: 17185464
references: J Immunol. 2000 Nov 1;165(9):5084-96
references: 11046039
references: Methods Mol Med. 2002;69:371-88
references: 11987790
references: Nat Rev Cancer. 2002 Mar;2(3):175-87
references: 11990854
references: J Biol Chem. 2003 Apr 18;278(16):14363-9
references: 12571250
references: Blood. 2003 Jun 1;101(11):4569-75
references: 12576322
references: N Engl J Med. 2003 Jun 26;348(26):2609-17
references: 12826635
references: J Biol Chem. 2004 Jun 18;279(25):26243-50
references: 15084608